Search results for " Preclinical"

showing 9 items of 159 documents

One pot light assisted green synthesis, storage and antimicrobial activity of dextran stabilized silver nanoparticles.

2014

Background Green synthesis of nanomaterials finds the edge over chemical methods due to its environmental compatibility. Herein, we report green synthesis of silver nanoparticles (Ag NPs) mediated with dextran. Dextran was used as a stabilizer and capping agent to synthesize Ag NPs using silver nitrate (AgNO3) under diffused sunlight conditions. Results UV–vis spectra of as synthesized Ag nanoparticles showed characteristic surface plasmon band in the range from ~405-452 nm. Scanning electron microscopy (SEM) and atomic force microscopy (AFM) studies showed spherical Ag NPs in the size regime of ~50-70 nm. Face centered cubic lattice of Ag NPs was confirmed by powder X-ray diffraction (PXRD…

inorganic chemicalsMaterials scienceSilverReducing agentScanning electron microscopeeducationBiomedical EngineeringDrug Evaluation PreclinicalMedicine (miscellaneous)Pharmaceutical ScienceMetal NanoparticlesNanotechnologyBioengineeringMicrobial Sensitivity TestsAntimicrobial activityMicroscopy Atomic ForceApplied Microbiology and BiotechnologySilver nanoparticleNanomaterialsStorage of nanoparticleschemistry.chemical_compoundAnti-Infective AgentsX-Ray DiffractionDiffused sun lightSpectroscopy Fourier Transform InfraredThin filmhealth care economics and organizationsAg nanoparticlesResearchtechnology industry and agricultureDextransGreen Chemistry TechnologySilver nitrateDextranchemistryMicroscopy Electron ScanningMolecular MedicineSilver NitrateSpectrophotometry UltravioletPowder diffractionNuclear chemistryJournal of nanobiotechnology
researchProduct

Effects of Mn2+ on the responses induced by different spasmogens in the oestrogen-primed rat uterus

1997

Abstract We investigated the effect of Mn 2+ on the mechanical responses evoked by high K + (60 mM) or low Na + (25 mM) solutions, oxytocin and neurokinin A in the oestrogen-primed rat uterus. In a Ca 2+ -free, Mn 2+ (0.54 mM)-containing solution, high K + or low Na + solutions produced contractions of smaller amplitude than those observed in a normal Ca 2+ (0.54 mM) solution, which were abolished by nifedipine (1 μM). Oxytocin (1 μM) and neurokinin A (1 μM, in the presence of phosphoramidon 1 μM) evoked nifedipine-insensitive contractile responses similar to (oxytocin) or smaller (neurokinin A) in amplitude than those observed in Ca 2+ (0.54 mM)-containing solution. In strips loaded with C…

medicine.medical_specialtyContraction (grammar)Inositol PhosphatesNeurokinin ADrug Evaluation PreclinicalIn Vitro TechniquesOxytocinUterine Contractionchemistry.chemical_compoundInternal medicinemedicineAnimalsRats WistarPharmacologyManganeseSodiumPhosphoramidonMyometriumEstrogensElectric StimulationRatsEGTAEndocrinologychemistryOxytocinPotassiumCalciumFemaleNeurokinin Amedicine.symptomCyclopiazonic acidMuscle contractionmedicine.drugEuropean Journal of Pharmacology
researchProduct

Impact of pharmacological and psychological treatment methods of depressive and anxiety disorders on cognitive functioning

2014

Anxiety and depressive disorders are characterized by a number of clinical symptoms like decreased mood, apathy, anhedonia and anxiety. An important element of the clinical picture is also neurocognitive impairment. The most common treatment methods for depression and anxiety are pharmacology, psychotherapy or a combination of both methods. The data from literature show that those treatment methods lead to an improvement of clinical symptoms, but they exert a possible impact on cognitive functions. However the study results referring both to the role of pharmacological treatment and psychotherapy in this domain are still inconsistent. There is an increasing number of accessible data confirm…

medicine.medical_specialtyNeurologyClinical NeurologyPsychological interventionAnxietyPsychiatry and Preclinical Psychiatric Studies - Review articlemedicineHumansApathyCognitive skillPsychiatryBiological PsychiatryPsychotropic DrugsDepressionAnhedoniaCognitionAnxiety DisordersDatabases BibliographicPharmacotherapyCognitive functionsPsychotherapyPsychiatry and Mental healthNeurologyAnxietyNeurology (clinical)medicine.symptomCognition DisordersPsychologyNeurocognitiveClinical psychologyJournal of Neural Transmission : Translational Neuroscience, Neurology and Preclinical Neurological Studies, Psychiatry and Preclinical Psychiatric Studies
researchProduct

Selected peptides targeted to the NMDA receptor channel protect neurons from excitotoxic death

1998

Excitotoxic neuronal death, associated with neurodegeneration and stroke, is triggered primarily by massive Ca2+ influx arising from overactivation of glutamate receptor channels of the N-methyl-D-aspartate (NMDA) subtype. To search for channel blockers, synthetic combinatorial libraries were assayed for block of agonist-evoked currents by the human NR1-NR2A NMDA receptor subunits expressed in amphibian oocytes. A set of arginine-rich hexapeptides selectively blocked the NMDA receptor channel with IC50 approximately 100 nM, a potency similar to clinically tolerated blockers such as memantine, and only marginally blocked on non-NMDA glutamate receptors. These peptides prevent neuronal cell d…

medicine.medical_specialtyXenopusDrug Evaluation PreclinicalBiomedical EngineeringBioengineeringHippocampal formationBiologyPharmacologyArginineBinding CompetitiveHippocampusReceptors N-Methyl-D-AspartateApplied Microbiology and BiotechnologySubstrate SpecificityInternal medicinemedicineAnimalsHumansChannel blockerReceptorNeuronsCell DeathNeurodegenerationGlutamate receptorMemantinemedicine.diseaseRatsEndocrinologymedicine.anatomical_structurenervous systemDrug DesignOocytesMolecular MedicineNMDA receptorFemaleNeuronPeptidesBiotechnologymedicine.drugNature Biotechnology
researchProduct

The Potential Use of Resveratrol for Cancer Prevention.

2019

In addition to the traditional treatments of cancer and cancer prevention, the use of natural compounds, especially those found in food, should be considered. To clarify if resveratrol has the potential for cancer prevention and the possibility of use in therapy, the following must be taken into account: data from epidemiology, clinical protocol (case and control), preclinical studies (lab animals), use of established cell lines as models of cancer cells, test tube assays (enzymes activities), and requirements of nanotechnologies in order to discover new drugs to fight cancer. From this perspective and future expected advances, more information is needed such as improved efficacy, methods o…

medicine.medical_treatmentDrug Evaluation PreclinicalPharmaceutical ScienceReviewResveratrolresveratrolBioinformaticsChemopreventionAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinepreventionNeoplasmsDrug DiscoverymedicineAnimalsHumanscancerPhysical and Theoretical ChemistrySensitization030304 developmental biology0303 health sciencesmechanismsCancer preventionbusiness.industryOrganic ChemistryClinical Studies as TopicCancerDisease Managementmedicine.diseaseAntineoplastic Agents PhytogenicBioavailabilitymedicine.anatomical_structurechemistryChemistry (miscellaneous)030220 oncology & carcinogenesisapproach strategiesCancer cellMolecular MedicineDisease Susceptibilitybusinessinnovative formulationsAdjuvantSignal TransductionMolecules (Basel, Switzerland)
researchProduct

COX-2 expression in chondrosarcoma: A role for celecoxib treatment?

2010

Chondrosarcomas are resistant to conventional chemo- and radiotherapy. A subset of chondrosarcomas arises secondarily in the benign tumour syndromes enchondromatosis (EC) and multiple osteochondromas (MO), and prevention of tumour development would greatly improve prognosis. We therefore investigated the effect of selective COX-2 inhibition on chondrosarcoma growth. COX-2 expression was studied in central- and peripheral cartilaginous tumours. The effect of COX-2 inhibition was assessed in four high-grade chondrosarcoma cell lines using celecoxib and NS-398 treatment. COX-2 activity (prostaglandin E-2 (PGE(2)) ELISA) and cell viability were measured. The (prophylactic) effect of celecoxib o…

musculoskeletal diseasesMaleCancer ResearchPathologymedicine.medical_specialtyCell Survivalmedicine.medical_treatmentChondrosarcomaDrug Evaluation PreclinicalMice NudeAntineoplastic AgentsBone NeoplasmsMiceIn vivomedicineTumor Cells CulturedAnimalsHumansViability assaySulfonamidesCyclooxygenase 2 Inhibitorsbusiness.industryCartilagemedicine.diseaseXenograft Model Antitumor AssaysRadiation therapyDisease Models Animalmedicine.anatomical_structureOncologyBone tumours Chondrosarcoma COX-2 inhibition Therapy Xenograft familial adenomatous polyposis cell-line cyclooxygenase-2 inhibitor trial tumors establishment emphasis origin boneCell cultureCelecoxibCyclooxygenase 2CelecoxibPyrazolesChondrosarcomabusinessmedicine.drugProstaglandin E
researchProduct

Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis.

2008

Contains fulltext : 70589.pdf (Publisher’s version ) (Closed access) OBJECTIVE: CO-releasing molecules (CO-RMs) are a novel class of anti-inflammatory agents. We have examined the possible therapeutic effects of CORM-3 in collagen-induced arthritis (CIA). METHODS: Arthritis was induced in DBA-1/J mice by type II collagen. Animals were treated with CORM-3 (5 and 10 mg/kg/day, intraperitoneally) or the inactive compound iCORM-3 (10 mg/kg/day, intraperitoneally) unable to release CO, from days 22 to 31. Production of anti-type II collagen antibodies, cytokines and cartilage olimeric matrix protein (COMP) was evaluated by enzyme-linked immunosorbent assay, and prostaglandin E(2) (PGE(2)) by rad…

musculoskeletal diseasesmedicine.medical_treatmentImmunologyAnti-Inflammatory AgentsDrug Evaluation PreclinicalType II collagenArthritisInflammationPharmacologyAuto-immunity transplantation and immunotherapy [N4i 4]DinoprostoneGeneral Biochemistry Genetics and Molecular BiologyMiceRheumatologyOrganometallic CompoundsPerception and Action [DCN 1]medicineAnimalsImmunology and AllergyChronic inflammation and autoimmunity [UMCN 4.2]Dose-Response Relationship Drugbiologybusiness.industryRANK LigandInterleukinIntercellular Adhesion Molecule-1medicine.diseaseArthritis ExperimentalPathogenesis and modulation of inflammation [N4i 1]Cellular infiltrationCyclooxygenase 2Mice Inbred DBARANKLImmunologybiology.proteinCytokinesTumor necrosis factor alphaMicrobial pathogenesis and host defense [UMCN 4.1]Inflammation Mediatorsmedicine.symptombusinessInfection and autoimmunity [NCMLS 1]Heme Oxygenase-1Immunity infection and tissue repair [NCMLS 1]Prostaglandin E
researchProduct

Realization of polyaspartamide-based nanoparticles and in vivo lung biodistribution evaluation of a loaded gucocorticoid after aerosolization in mice

2016

Abstract In this study, novel polymeric nanoparticles (NPs) were developed and their potential as carriers for beclomethasone dipropionate (BDP) into the lung after aerosolization was demonstrated by in vivo studies in mice. In particular, these NPs were obtained starting from two polyaspartamide-based copolymers which were synthesized by chemical reaction of α,β-poly(N-2-hydroxyethyl)- dl -aspartamide (PHEA) and its pegylated derivative (PHEA-PEG2000) with poly(lactic acid) (PLA). To obtain nanosized particles, the high pressure homogenization (HPH)—solvent evaporation method was followed by using an organic phase containing both PHEA-PLA and PHEA-PEG2000-PLA (at a weight ratio equal to 1:…

polymeric nanoparticles beclomethasone dipropionate aerosolization in miceBiodistributionDrug Evaluation PreclinicalPolymeric nanoparticles Beclomethasone dipropionate (BDP) PolyhydroxyethylaspartamidePharmaceutical ScienceNanotechnology02 engineering and technology010402 general chemistry01 natural scienceschemistry.chemical_compoundMicePulmonary surfactantIn vivoPEG ratioAdministration InhalationmedicineAnimalsTissue DistributionGlucocorticoidsLungAerosolizationAerosolsChromatographyLungmedicine.diagnostic_testtechnology industry and agricultureBeclomethasonerespiratory system021001 nanoscience & nanotechnology0104 chemical sciencesLactic acidBronchoalveolar lavagemedicine.anatomical_structurechemistryNanoparticles0210 nano-technologyPeptidesBronchoalveolar Lavage Fluid
researchProduct

Dipeptidyl Enoates As Potent Rhodesain Inhibitors That Display a Dual Mode of Action

2015

Dipeptidyl enoates were prepared through a high-yielding two-step synthetic route. They have a dipeptidic structure with a 4-oxoenoate moiety as a warhead with multiple reactive sites. Dipeptidyl enoates were screened against rhodesain and human cathepsins B and L, and were found to be potent and selective inhibitors of rhodesain. Among them (S,E)-ethyl 5-((S)-2-{[(benzyloxy)carbonyl]amino}-3-phenylpropanamido)-7-methyl-4-oxooct-2-enoate (6) was the most potent, with an IC50 value of 16.4 nm and kinact/Ki=1.6×106 m−1 s−1 against rhodesain. These dipeptidyl enoates display a reversible mode of inhibition at very low concentrations and an irreversible mode at higher concentrations. Inhibition…

trypanosomiasisStereochemistrysleeping sicknessCathepsin LDrug Evaluation PreclinicalChemistry Techniques SyntheticInhibition kineticsCysteine Proteinase InhibitorsBiochemistryCathepsin BInhibitory Concentration 50Structure-Activity RelationshipinhibitorsDrug DiscoveryHumansMoietyMolecular Targeted TherapyGeneral Pharmacology Toxicology and PharmaceuticsIC50Volume concentrationrhodesainPharmacologyChemistryOrganic ChemistryDual modeDipeptidesTrypanocidal AgentsCombinatorial chemistryMolecular Docking SimulationCysteine EndopeptidasesKineticsdipeptidyl enoatesTrypanosomiasis AfricanDocking (molecular)Molecular MedicineCysteine thiolateChemMedChem
researchProduct